Irrespective of whether these findings were due to a link with the (prognostic) HER2 amplification or the role of TOP2A as a parameter for high tumor cell proliferation, the lack of a prognostic impact of TOP2A expression in our patients is again consistent with HER2- and/or proliferation-associated treatment effects. Here, ERBB2 is linked to neoplasm.